Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -4.72% is in line with its 5-year average of -4.37%, near the high end of its 5-year range (-2296.90%–33.25%).
141.33% below its 12-month average of -1.96%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 13.67%.
EBITDA MARGIN
-4.72%
EBITDA MARGIN AVG TTM
-1.96%
EBITDA MARGIN AVG 3Y
-3.55%
EBITDA MARGIN AVG 5Y
-4.37%
EBITDA MARGIN AVG 10Y
10.75%
EBITDA MARGIN AVG 15Y
22.97%
EBITDA MARGIN AVG 20Y
23.19%
CURRENT VS TTM AVG
-141.33%
CURRENT VS 3Y AVG
-33.00%
CURRENT VS 5Y AVG
-8.08%
CURRENT VS 10Y AVG
-143.92%
CURRENT VS 15Y AVG
-120.55%
CURRENT VS 20Y AVG
-120.36%
Anika Therapeutics, Inc.
Market Cap
$264.05M
EBITDA Margin
-4.72%
TTM Avg
-1.96%
3Y Avg
-3.55%
5Y Avg
-4.37%
Market Cap
$264.07M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$266.62M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
Market Cap
$267.99M
EBITDA Margin
-1.78%
TTM Avg
-948.17%
3Y Avg
-2570.36%
5Y Avg
-2570.36%
Market Cap
$261.48M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$276.82M
EBITDA Margin
-1857.26%
TTM Avg
-1020.57%
3Y Avg
-1032.24%
5Y Avg
-903.20%
Market Cap
$283.69M
EBITDA Margin
-13.37%
TTM Avg
-2.68%
3Y Avg
-19.85%
5Y Avg
-36.16%
Market Cap
$252.90M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
Market Cap
$249.82M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $264.05M | -4.72% | -1.96% | -3.55% | -4.37% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.07M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.62M | -768.62% | -551.06% | -374.75% | -290.29% |
| Century Therapeutics, Inc. (IPSC)vs › | $267.99M | -1.78% | -948.17% | -2570.36% | -2570.36% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.48M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $276.82M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
| Aurora Cannabis Inc. (ACB)vs › | $283.69M | -13.37% | -2.68% | -19.85% | -36.16% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $252.90M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $247.45M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
Gross Margin
62.2%
EBITDA Margin
-4.7%
Operating Margin
-4.2%
Net Margin
-3.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 13.67% |
| 2026-03-31 | -13.78% |
| 2025-12-31 | 6.42% |
| 2025-09-30 | -6.59% |
| 2025-06-30 | -9.50% |
| 2025-03-31 | -10.29% |
| 2024-12-31 | -2296.90% |
| 2024-09-30 | -66.65% |
| 2024-06-30 | 0.81% |
| 2024-03-31 | -6.08% |
| 2023-12-31 | -140.11% |
| 2023-09-30 | -9.97% |
| 2023-06-30 | -0.18% |
| 2023-03-31 | -23.74% |
| 2022-12-31 | -7.57% |
| 2022-09-30 | -5.72% |
| 2022-06-30 | 0.83% |
| 2022-03-31 | 0.17% |
| 2021-12-31 | -15.06% |
| 2021-09-30 | 12.33% |
| 2021-06-30 | 33.25% |
| 2021-03-31 | 13.90% |
| 2020-12-31 | -44.21% |
| 2020-09-30 | -13.96% |
| 2020-06-30 | -19.03% |
| 2020-03-31 | 27.84% |
| 2019-12-31 | 21.28% |
| 2019-09-30 | 45.68% |
| 2019-06-30 | 43.01% |
| 2019-03-31 | 29.35% |
| 2018-12-31 | 41.69% |
| 2018-09-30 | 37.65% |
| 2018-06-30 | 41.55% |
| 2018-03-31 | -29.91% |
| 2017-12-31 | 36.73% |
| 2017-09-30 | 42.20% |
| 2017-06-30 | 55.99% |
| 2017-03-31 | 38.57% |
| 2016-12-31 | 47.68% |
| 2016-09-30 | 56.48% |
| 2016-06-30 | 54.28% |
| 2016-03-31 | 52.29% |
| 2015-12-31 | 58.39% |
| 2015-09-30 | 59.58% |
| 2015-06-30 | 58.25% |
| 2015-03-31 | 41.35% |
| 2014-12-31 | 56.83% |
| 2014-09-30 | 52.12% |
| 2014-06-30 | 62.30% |
| 2014-03-31 | 73.71% |
| 2013-12-31 | 54.70% |
| 2013-09-30 | 51.11% |
| 2013-06-30 | 50.25% |
| 2013-03-31 | 40.75% |
| 2012-12-31 | 39.60% |
| 2012-09-30 | 26.47% |
| 2012-06-30 | 37.35% |
| 2012-03-31 | 28.20% |
| 2011-12-31 | 32.39% |
| 2011-09-30 | 31.53% |
| 2011-06-30 | 29.11% |
| 2011-03-31 | 12.58% |
| 2010-12-31 | 22.71% |
| 2010-09-30 | 20.71% |
| 2010-06-30 | 18.03% |
| 2010-03-31 | 16.27% |
| 2009-12-31 | 17.88% |
| 2009-09-30 | 21.73% |
| 2009-06-30 | 16.20% |
| 2009-03-31 | 11.88% |
| 2008-12-31 | 17.84% |
| 2008-09-30 | 18.16% |
| 2008-06-30 | 13.97% |
| 2008-03-31 | 13.13% |
| 2007-12-31 | 24.96% |
| 2007-09-30 | 25.98% |
| 2007-06-30 | 21.83% |
| 2007-03-31 | 22.55% |
| 2006-12-31 | 16.32% |
| 2006-09-30 | 29.15% |
| 2006-06-30 | 24.58% |
| 2006-03-31 | 16.20% |
| 2005-12-31 | 17.80% |
| 2005-09-30 | 40.17% |
| 2005-06-30 | 29.66% |
| 2005-03-31 | 26.25% |
| 2004-12-31 | 33.65% |
| 2004-09-30 | 26.41% |
| 2004-06-30 | 23.32% |
| 2004-03-31 | 22.31% |
| 2003-12-31 | 21.78% |
| 2003-09-30 | 17.43% |
| 2003-06-30 | 3.83% |
| 2003-03-31 | -7.71% |
| 2002-12-31 | 21.39% |
| 2002-09-30 | -16.17% |
